




RealRate

PHARMACEUTICAL 2015

Dynavax Technologies CORP
Rank 148 of 274

DYNVAX



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Dynavax Technologies CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dynavax Technologies CORP compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 50% points. The greatest weakness of Dynavax Technologies CORP is the variable Research and Development, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 264%, being 10% points above the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	127,437
Cost of Goods Sold	0
Intangible Assets	2,277
Liabilities, Current	20,279
Liabilities, Non-Current	1,070
Other Assets	652
Other Compr. Net Income	-1,521
Other Expenses	421
Other Liabilities	16,459
Other Net Income	624
Other Revenues	11,032
Property and Equipment	7,924
Research and Development	84,580
Selling, General and Administrative Expense	17,377

Output Variable	Value in 1000 USD
Assets	138,290
Liabilities	37,808
Expenses	102,378
Revenues	11,032
Stockholders Equity	100,482
Net Income	-90,722
Comprehensive Net Income	-91,482
BaseVar	145,826
ECR before LimitedLiability	145%
Economic Capital Ratio	264%